If a recent New York Times piece is any guide, direct-to-consumer genetic testing may have more accuracy problems than we thought. Reporter Kira Peikoff ordered three simultaneous tests of her genome from 23andme, Genetic Testing Laboratories, and Pathway Genomics — and the results varied more widely than you might think. According to 23andme, she had an elevated risk of psoriasis, with a lifetime risk of 20.2 percent, but GTL put her lifetime risk at only two percent, well below average. ...{br}{br}View the Entire Article{br}